Could GlaxoSmithKline plc Become A Perilous Value Trap?

Royston Wild explains why GlaxoSmithKline plc (LON: GSK) may not be the dirt-cheap darling it appears to be.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in pharma giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have suffered a rather miserable end to what has proved for the most part a hugely tumultuous year. Prices are currently down 11% in the month to date and are within touching distance of punching a fresh three-year trough below 1,325p per share.

A plucky candidate on paper

For value investors, however, this recent weakness has provided fresh opportunity to plough into the medicines play.

Although the impact of sales-smashing exclusivity losses is expected to shove earnings 18% lower during 2014, GlaxoSmithKline still deals on a decent P/E rating of 14.7 times — any reading below 15 times is generally considered attractive bang for your buck. And expectations of a fractional earnings uptick in 2015 pushes this to just 14.5 times.

And for dividend hunters GlaxoSmithKline is an even more appetising proposition, with the firm expected to deliver dividend increases to the tune of 3% and 1% in 2014 and 2015 correspondingly. As a result the business sports a chunky yield of 5.9% through to the close of next year, blasting a forward average of 3.3% for the complete FTSE 100 clean out of the water.

Revenues growth to remain elusive?

However, I believe there are a number of issues still facing GlaxoSmithKline which could derail these earnings and dividends forecasts.

Firstly the business still needs to get to grips with the enduring problem of patent losses covering a number of key products, and eroding protection for its Advair anti-asthma treatment in particular is likely to hamper sales growth the coming years — revenues for this label slumped 25% during July-September alone.

GlaxoSmithKline has beefed up its R&D pipeline to deal with these losses, and currently has around 20 potential earnings drivers in late-stage development. Still, the persistent threat of setbacks from lab bench to pharmacy shelf — not to mention the work of its industry rivals in similar healthcare areas — does not guarantee to replace the lost revenues resulting from patent expirations.

Indeed, GlaxoSmithKline’s failure to hive off its portfolio of ‘older’ drugs which have lost exclusivity protection illustrates the possible lack of value that these products are likely to have going forward, a development which has no doubt taken the business by surprise.

On top of this, government and private health plans are increasingly playing hardball with ‘big pharma’ in a bid to drive down what they fork out for drugs, another potential turnover-smacker for the likes of GlaxoSmithKline.

I believe that GlaxoSmithKline’s vast cash flows should facilitate robust drugs development in the coming years, achieved through a combination of in-house R&D and further frantic acquisition activity, and consequently deliver a return to earnings growth. But there are many bumps in the road which could seriously undermine this recovery and disappoint value hunters, both in the near- and long-term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »